Physician profile
Zachary Andrew Borman
NPI 1922412436
$520,183.69
in general payments reported to CMS, 2019-2025
42 companies · $202K in 2025
The $202K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $178 · 2021: $412 · 2022: $53K · 2023: $92K · 2024: $173K · 2025: $202K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $305K · Travel and Lodging: $66K · Consulting Fee: $62K · Food and Beverage: $26K · Honoraria: $6,290 · Education: $1,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $304,899.96 |
| Travel and Lodging | $65,648.03 |
| Consulting Fee | $61,893.50 |
| Food and Beverage | $26,202.02 |
| Honoraria | $6,290.00 |
| Education | $1,444.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $133,429.75 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $116,143.32 | 2019-2024 | Zeposia |
| Pfizer INC. | $81,201.05 | 2022-2025 | |
| Abbvie INC. | $71,248.57 | 2022-2025 | Rinvoq, Skyrizi, Linzess |
| Celltrion USA INC. | $39,393.95 | 2024-2025 | Zymfentra, Vegzelma |
| Janssen Scientific Affairs, LLC | $21,882.23 | 2022-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $20,730.17 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $9,534.37 | 2023-2025 | Omvoh, Zepbound |
| Eli Lilly and Company | $8,796.95 | 2024-2025 | Omvoh |
| Celgene Corporation | $7,724.09 | 2021-2024 | Zeposia |
| Genzyme Corporation | $2,945.49 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,340.10 | 2022-2025 | Entyvio, Gattex |
| Mahana Therapeutics, INC. | $900.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $891.54 | 2020-2025 | Xifaxan, Trulance, Plenvu |
| Regeneron Healthcare Solutions, INC. | $863.69 | 2022-2025 | Dupixent |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $777.90 | 2020-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $645.99 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $254.43 | 2023-2025 | Vowst, Zenpep |
| Madrigal Pharmaceuticals | $182.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Fujifilm Healthcare Americas Corporation | $147.00 | 2019 | |
| Medtronic, INC. | $128.63 | 2022-2024 | Gi Genius |
| Daiichi Sankyo INC. | $127.84 | 2023-2025 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.71 | 2023 | Cyltezo |
| Boston Scientific Corporation | $100.74 | 2022 | |
| Sandoz INC. | $93.56 | 2023 | Hyrimoz |
| Braintree Laboratories, INC. | $83.36 | 2021-2023 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $71.46 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $61.77 | 2023-2024 | Rebyota, Cimzia |
| Caris Mpi, INC. | $58.80 | 2025 | Mi Cancer Seek |
| Capsovision, INC. | $32.18 | 2024 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $31.55 | 2023-2024 | Dificid, Zinplava |
| Pharmacosmos Therapeutics INC. | $30.40 | 2025 | Monoferric |
| Gilead Sciences, INC. | $24.94 | 2024 | |
| Exact Sciences Corporation | $24.87 | 2024 | Cologuard Collection Kit |
| Micro-Tech Endoscopy USA, INC. | $21.17 | 2025 | Lesionhunter |
| Nestle Healthcare Nutrition INC. | $21.07 | 2023 | |
| Fresenius Kabi USA, LLC | $20.40 | 2023 | Idacio |
| Organon LLC | $19.35 | 2023 | Hadlima, Renflexis |
| Covidien Lp | $19.32 | 2019 | |
| Enterra Medical, INC. | $18.15 | 2024 | |
| Evoke Pharma, INC. | $16.96 | 2025 | |
| Redhill Biopharma INC. | $16.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Borman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.